COST OF INDIVIDUALIZING AMINOGLYCOSIDE DOSAGE REGIMENS

被引：20

作者：

BOOTMAN, JL ^{[1
]}

ZASKE, DE ^{[1
]}

WERTHEIMER, AI ^{[1
]}

ROWLAND, C ^{[1
]}

机构：

[1] UNIV MINNESOTA,COLL PHARM,MINNEAPOLIS,MN 55455

来源：

AMERICAN JOURNAL OF HOSPITAL PHARMACY | 1979年 / 36卷 / 03期

关键词：

D O I：

10.1093/ajhp/36.3.368

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：368 / 370

页数：3

共 8 条

[1] Cohen M R, 1977, Hosp Pharm, V12, P9
[2] COHEN MR, 1977, HOSP PHARM, V12, P12
[3] COHEN MR, 1977, HOSP PHARM, V12, P19
[4] FEELY WT, 1973, HOSP PHARM, V8, P6
[5] PRESENT STATUS OF COST-BENEFIT ANALYSIS IN HEALTH FIELD
KLARMAN, HE
[J]. AMERICAN JOURNAL OF PUBLIC HEALTH AND THE NATIONS HEALTH, 1967, 57 (11): : 1948 - &
[6] COST-BENEFIT AND COST-EFFECTIVENESS - METHODOLOGIES FOR EVALUATING INNOVATIVE PHARMACEUTICAL SERVICES
MCGHAN, WF
ROWLAND, CR
BOOTMAN, JL
[J]. AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1978, 35 (02): : 133 - 140
[7] EXPERIENCE IN MONITORING GENTAMICIN THERAPY DURING TREATMENT OF SERIOUS GRAM-NEGATIVE SEPSIS
NOONE, P
PARSONS, TMC
PATTISON, JR
SLACK, RCB
GARFIELD.D
HUGHES, K
[J]. BRITISH MEDICAL JOURNAL, 1974, 1 (5906) : 477 - 481
[8] SOCIAL IMPACT OF PHARMACEUTICAL INNOVATION
WERTHEIMER, AI
BOOTMAN, JL
[J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1977, 3 (03) : 219 - 225